CTOs on the Move

Codiak Biosciences

www.codiakbio.com

 
Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth. Recent discoveries have ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.codiakbio.com
  • 500 Technology Square 9th Floor
    Woburn, MA USA 02139
  • Phone: 617.949.4100

Executives

Name Title Contact Details
Konstantin Konstantinov
Chief Technology Officer Profile

Funding

Codiak Biosciences raised $31M on 11/25/2015
Codiak Biosciences raised $76.5M on 11/29/2017
Codiak Biosciences raised $66.4M on 02/11/2021

Similar Companies

Jasper Clinical Research and Development

Jasper Clinical Research and Development is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Segra

Our solution: Segra leverages expertise in biochemistry, botany, plant tissue culture, genetic testing, and production under strict regulatory environments to bring end-to-end solutions for product production and sale in the medical Cannabis space.

Network Biosystems

Network Biosystems, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioMarin

BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. The efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. Our track record of developing and commercializing new treatments has been significantly faster than the industry average and is a remarkable accomplishment that is ingrained in our culture. The company`s product portfolio comprises five marketed products and multiple clinical and pre-clinical product candidates.

Enthalpy Analytical

Enthalpy Analytical, Inc. is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.